May 25, 2023 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Appointment of Kevin Hrusovsky as Venture Partner
May 23, 2023 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Appointment of Jami Rubin as Venture Partner
April 25, 2023 Media Coverage from ARCH Venture Partners | Share ARCH leads Series A for Orbital, supporting research to unleash full potential of RNA medicines
April 6, 2023 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner
March 7, 2023 Media Coverage from ARCH Venture Partners | Share ARCH leads Volastra $60 million financing round
January 27, 2023 Media Coverage from ARCH Venture Partners | Share The New York Times profiled ARCH-backed Paradigm, which aims to simplify clinical trials
December 15, 2022 Media Coverage from ARCH Venture Partners | Share Gates, Bezos back $75M round led by ARCH for Synchron’s drill-free brain-computer interface implant
December 8, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Patrick Weiss as Venture Partner
December 5, 2022 Media Coverage from ARCH Venture Partners | Share Gene therapy goes acoustic as ARCH-backed biotech launches with ultrasound gene delivery platform
November 21, 2022 Media Coverage from ARCH Venture Partners | Share With the clinic in sight, Greg Verdine’s startup bags $178M from ARCH for new class of targeted therapies
November 4, 2022 Media Coverage from ARCH Venture Partners | Share Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but ARCH-backed hC Bioscience climbs to Series A extension
September 12, 2022 Media Coverage from ARCH Venture Partners | Share Freshly baked: ARCH-backed Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell, Jay Parrish leads company as CEO and Chairman
